Objective:Since December 2019,an outbreak of corona virus disease 2019(COVID-19)occurred in Wuhan,and rapidly spread to almost all parts of China.This was followed by prevention programs recommending Chinese medicine(...Objective:Since December 2019,an outbreak of corona virus disease 2019(COVID-19)occurred in Wuhan,and rapidly spread to almost all parts of China.This was followed by prevention programs recommending Chinese medicine(CM)for the prevention.In order to provide evidenee for CM recommendations,we reviewed ancient classics and human studies.Methods:Historical records on prevention and treatment of infections in CM classics,clinical evidence of CM on the prevention of severe acute respiratory syndrome(SARS)and H1N1 in flue nza,and CM preve ntion programs issued by health authorities in China since the COVID-19 outbreak were retrieved from differe nt databases and websites till 12 February,2020.Research evide nee in eluded data from clinical trials,cohort or other population studies using CM for preventing contagious respiratory virus diseases.Results:The use of CM to prevent epidemics of infectious diseases was traced back to ancient Chinese practice cited in Huangdi's Internal Classic(Huang Di Nei Jing)where preventive effects were recorded.There were 3 studies using CM for prevention of SARS and 4 studies for H1N1 influenza.None of the participants who took CM contracted SARS in the 3 studies.The infection rate of H1N1 in flue nza in the CM group was significantly lower than the non-CM group(relative risk 0.36,95%confidence interval 0.24-0.52;n=4).For prevention of COVID-19,23 provinces in China issued CM programs.The main principles of CM use were to tonify qi to protect from external pathoge ns,disperse wind and discharge heat,and resolve damp ness.The most frequently used herbs in eluded Radix astragali(Huangqi),Radix glycyrrhizae(Gancao),Radix saposhnikoviae(Fangfeng),Rhizoma Atractylodis Macrocephalae(Baizhu),Lonicerae Japonicae Flos(Jinyinhua),and Fructus forsythia(Lianqiao).Conclusions:Based on historical records and human evidenee of SARS and H1N1 influenza prevention,Chinese herbal formula could be an alternative approach for prevention of COVID-19 in high-risk population.Prospective,rigorous population studies are warranted to confirm the potential preventive effect of CM.展开更多
目的 探寻宣肺解热颗粒治疗新型冠状病毒肺炎(Corona Virus Disease 2019,COVID-19)合并发热的作用机制。方法 用中药系统药理学数据库与分析平台(Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, ...目的 探寻宣肺解热颗粒治疗新型冠状病毒肺炎(Corona Virus Disease 2019,COVID-19)合并发热的作用机制。方法 用中药系统药理学数据库与分析平台(Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, TCMSP)筛选宣肺解热颗粒的有效组分,并预测潜在靶基因,并用GeneCards和CTD数据库检索新型冠状病毒肺炎合并发热的相关疾病靶点,得到上述二者共有的靶点,导入Cytoscape中构建“成分-靶点-疾病”网络。将上述二者共有的靶点输入STRING蛋白相互作用在线数据库,将得到的数据结果导入Cytoscape软件获得PPI(protein-protein interaction)网络;用R语言对共同靶点进行GO(Gene Ontology)与KEGG(Kyoto Encyclopedia of Genes and Genomes)富集分析。结果 经筛选得到活性成分84个、靶点82个。通路富集分析显示,宣肺解热颗粒治疗新型冠状病毒肺炎合并发热主要作用于蛋白激酶B(Protein kinase B,AKT1)、肿瘤蛋白P53(Tumor Protein P53,TP53)和白细胞介素-6(Interleukin-6,IL-6)等关键靶点。KEGG通路富集分析显示,主要与影响流体剪切应力与动脉粥样硬化、人巨细胞病毒感染和糖尿病并发症中的AGE-RAGE等信号通路有关。分子对接结果显示,核心靶点与β-谷甾醇、刺芒柄花素及N-反式阿魏酰酪胺等有较强的的亲和力。结论 本研究初步验证宣肺解热颗粒可通过多成分、多靶点和多通路来发挥治疗COVID-19合并发热的作用。展开更多
基金Supported by the National Natural Science Foundation of China(No.81830115),ChinaProf.Nicola Robinson(visiting professor of Beijing University of Chinese Medicine)is supported by the Overseas Expertise Project,Ministry of Education of China(No.MS20080009)。
文摘Objective:Since December 2019,an outbreak of corona virus disease 2019(COVID-19)occurred in Wuhan,and rapidly spread to almost all parts of China.This was followed by prevention programs recommending Chinese medicine(CM)for the prevention.In order to provide evidenee for CM recommendations,we reviewed ancient classics and human studies.Methods:Historical records on prevention and treatment of infections in CM classics,clinical evidence of CM on the prevention of severe acute respiratory syndrome(SARS)and H1N1 in flue nza,and CM preve ntion programs issued by health authorities in China since the COVID-19 outbreak were retrieved from differe nt databases and websites till 12 February,2020.Research evide nee in eluded data from clinical trials,cohort or other population studies using CM for preventing contagious respiratory virus diseases.Results:The use of CM to prevent epidemics of infectious diseases was traced back to ancient Chinese practice cited in Huangdi's Internal Classic(Huang Di Nei Jing)where preventive effects were recorded.There were 3 studies using CM for prevention of SARS and 4 studies for H1N1 influenza.None of the participants who took CM contracted SARS in the 3 studies.The infection rate of H1N1 in flue nza in the CM group was significantly lower than the non-CM group(relative risk 0.36,95%confidence interval 0.24-0.52;n=4).For prevention of COVID-19,23 provinces in China issued CM programs.The main principles of CM use were to tonify qi to protect from external pathoge ns,disperse wind and discharge heat,and resolve damp ness.The most frequently used herbs in eluded Radix astragali(Huangqi),Radix glycyrrhizae(Gancao),Radix saposhnikoviae(Fangfeng),Rhizoma Atractylodis Macrocephalae(Baizhu),Lonicerae Japonicae Flos(Jinyinhua),and Fructus forsythia(Lianqiao).Conclusions:Based on historical records and human evidenee of SARS and H1N1 influenza prevention,Chinese herbal formula could be an alternative approach for prevention of COVID-19 in high-risk population.Prospective,rigorous population studies are warranted to confirm the potential preventive effect of CM.
文摘目的 探寻宣肺解热颗粒治疗新型冠状病毒肺炎(Corona Virus Disease 2019,COVID-19)合并发热的作用机制。方法 用中药系统药理学数据库与分析平台(Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, TCMSP)筛选宣肺解热颗粒的有效组分,并预测潜在靶基因,并用GeneCards和CTD数据库检索新型冠状病毒肺炎合并发热的相关疾病靶点,得到上述二者共有的靶点,导入Cytoscape中构建“成分-靶点-疾病”网络。将上述二者共有的靶点输入STRING蛋白相互作用在线数据库,将得到的数据结果导入Cytoscape软件获得PPI(protein-protein interaction)网络;用R语言对共同靶点进行GO(Gene Ontology)与KEGG(Kyoto Encyclopedia of Genes and Genomes)富集分析。结果 经筛选得到活性成分84个、靶点82个。通路富集分析显示,宣肺解热颗粒治疗新型冠状病毒肺炎合并发热主要作用于蛋白激酶B(Protein kinase B,AKT1)、肿瘤蛋白P53(Tumor Protein P53,TP53)和白细胞介素-6(Interleukin-6,IL-6)等关键靶点。KEGG通路富集分析显示,主要与影响流体剪切应力与动脉粥样硬化、人巨细胞病毒感染和糖尿病并发症中的AGE-RAGE等信号通路有关。分子对接结果显示,核心靶点与β-谷甾醇、刺芒柄花素及N-反式阿魏酰酪胺等有较强的的亲和力。结论 本研究初步验证宣肺解热颗粒可通过多成分、多靶点和多通路来发挥治疗COVID-19合并发热的作用。
